New code Q5166: Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg — effective Jul 1, 2026

Sent Jul 23, 2026 · . This is the issue exactly as subscribers received it.

Effective Jul 1, 2026 · Q5166

New code Q5166: Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg

CMS assigned a new HCPCS code. Claims with dates of service on or after Jul 1, 2026 should use Q5166. Load it into your charge master, billing system, and prior-auth templates.

Code facts

HCPCS codeQ5166
DescriptorInjection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
1 billing unit1 mg
Effective dateJul 1, 2026

Products billed under Q5166

ProductPackageNDC (11-digit, claim form)WAC
Osvyrti (denosumab-desu)
biosimilar to Prolia — osteoporosis indications
60 mg/mL single-dose prefilled syringe (1 per pack) 69448-0021-63
10-digit: 69448-021-63
$1,800.41
$30.01 per 1 mg
Jubereq (denosumab-desu)
biosimilar to Xgeva — oncology indications
120 mg/1.7 mL (70 mg/mL) single-dose vial (1 per carton) 69448-0022-63
10-digit: 69448-022-63
$3,311.75
$27.60 per 1 mg

WAC = wholesale acquisition cost, from the manufacturer's announcement. It is not what any plan pays and excludes discounts and rebates.

Before you bill

No ASP-based Medicare payment limit yet: new codes typically pay from WAC until CMS publishes ASP for them (usually about two quarters after launch). Check your MAC's guidance.

Prolia family billing reference (J0897) →  ·  Xgeva family billing reference →  ·  Biosimilar modifier rules →

Estimating what patients owe on the new code? CareCost re-quotes a patient in about 90 seconds — free during beta.

Compiled from the CMS Q5166 HCPCS assignment (effective July 1, 2026) and Accord BioPharma's coding announcement for Osvyrti and Jubereq. WAC figures are the manufacturer's published wholesale acquisition costs and are not payer rates.